NLM Digital Collections

Search

Start Over Subjects Cost-Benefit Analysis ✖Remove constraint Subjects: Cost-Benefit Analysis Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later Publication Year 2017 ✖Remove constraint Publication Year: <span class="single" data-blrl-single="2017">2017</span>

1. Targeted immune modulators for rheumatoid arthritis: effectiveness and value : evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 7, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Arthritis, Rheumatoid -- immunology
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Drug Therapy, Combination
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Janus Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Tumor Necrosis Factors -- antagonists & inhibitors
Humans
United States

2. Dupilumab and crisaborole for atopic dermatitis: effectiveness and value : final evidence report and meeting summary

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, June 8, 2017
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Dermatitis, Atopic -- drug therapy
Interleukin-4 Receptor alpha Subunit -- antagonists & inhibitors
Phosphodiesterase 4 Inhibitors -- therapeutic use
Antibodies, Monoclonal -- adverse effects
Cost-Benefit Analysis
Cyclosporine -- therapeutic use
Phosphodiesterase 4 Inhibitors -- adverse effects
Phototherapy
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

3. Abuse-deterrent formulations of opioids: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, August 8, 2017
Subject(s):
Abuse-Deterrent Formulations -- economics
Abuse-Deterrent Formulations -- statistics & numerical data
Analgesics, Opioid -- economics
Analgesics, Opioid -- therapeutic use
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- prevention & control
Prescription Drug Diversion -- statistics & numerical data
Comparative Effectiveness Research
Cost-Benefit Analysis
Delayed-Action Preparations -- economics
Delayed-Action Preparations -- therapeutic use
Drug Compounding -- economics
Drug Overdose -- mortality
Insurance Coverage -- economics
Insurance, Pharmaceutical Services -- economics
Opioid-Related Disorders -- epidemiology
Humans
United States

4. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 6, 2017
Subject(s):
Comparative Effectiveness Research
Multiple Sclerosis, Chronic Progressive -- drug therapy
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- economics
Antirheumatic Agents -- therapeutic use
Benchmarking
Cost-Benefit Analysis
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- economics
Immunosuppressive Agents -- therapeutic use
Insurance Coverage
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

5. Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 10, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Immunotherapy
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Protein Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Value-Based Purchasing
Humans
United States